! ILC deserves much more attention from both clinical investigators and pharmaceutical industries! Very proud to present our poster on the lack of attention for ILC in clinical trials at #ESMOBreast2023. Josephine Van Cauwenberge Christine Desmedt Lobular Breast Cancer Alliance ELBCC

Proud to have presented our poster at #ESMOBreast2023, highlighting the lack of reporting BMI in recent breast cancer clinical trials. KarenVanBaelen Christine Desmedt

Proud to present this poster at the ILC symposium with KarenVanBaelen. We’ve pointed out the lack of reporting of lobular breast cancer in recent drug trials #ILCSymposium Christine Desmedt Lobular Breast Cancer Alliance ELBCC

Had a wonderful time at SABCS 2023, proud to present my poster about the value of Mammaprint in clinical low risk patients. Also, very happy to see the extra attention for lobular breast cancer, let’s continue this effort 💪🏻 #SABCS23 #mammaprint

Our Lobular Breast Cancer Session #SABCS23 made possible by SABCS and AACR a wonderful foundation on which to build. Amazing team work #Globmob Thank you all for embracing our patient advocates involvement in your Research ELBCC Lobular Breast Cancer Alliance

Headed to another conference soon? Mobile data hassles are history thanks to Firsty! I've tried it in the USA: user-friendly and...it's free! Another way to continue our global dialogue! So proud to be on the sideline of this project! (firsty.app) #firsty

Obesity➡️ worse prognosis & different biology #breastcancer. Still, BMI is only reported in 8% of 495 trials we reviewed. More research needed to study impact of BMI on treatment efficacy and toxicity🙏 ! Josephine Van Cauwenberge KarenVanBaelen OncoAlert doi.org/10.1186/s13058…